Idéal Investisseur Galteron Galteron
Français English
CAC 40 : Market open
8 310,79 pts
-0.49%


Last updated : 17/11/2026 - 09h31
🏠 Home   ➤    Stock news

Vetoquinol receives FDA approval for its antiparasitic Felpreva in the United States

The veterinary laboratory announced on November 16, 2026 that the Food & Drug Administration had authorized the marketing of Felpreva in the United States, an antiparasitic for cats already sold in Europe.

Its chairman and chief executive officer said he was pleased to be able to offer it to American veterinarians and cat owners.


Vetoquinol receives FDA approval for its antiparasitic Felpreva in the United States

A broad-spectrum topical treatment applied four times a year

Felpreva is a broad-spectrum antiparasitic intended for cats. It is administered as a topical treatment, with only four applications per year. In the United States as in Europe, it is dispensed only on prescription and reserved exclusively for cats.

Matthieu Frechin, chairman and chief executive officer of Vetoquinol, summarized the product's core argument as follows: “Felpreva simplifies parasite control for both veterinarians and cat owners by offering a simple solution: fewer applications for treatment and broad-spectrum protection.”

After a European launch in 2022, the opening of the American market

Launched in Europe in 2022, Felpreva has, according to the company, “gained the trust of European veterinarians and cat owners.” The FDA authorization now paves the way for its commercialization in the United States.

Founded in 1933 and listed on Euronext Paris since 2006, Vetoquinol specializes exclusively in animal health and operates in Europe, the Americas and Asia-Pacific. The group will publish its 2026 annual revenue on January 14, 2027, after the market closes.

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis


Sector Pharmacie et biotechnologies › Pharmacie, vaccins et santé animale


Context

Period
  • Period: 9M 2026
Key reported figures
  • Revenue: 399 millions d'euros
  • Quarterly revenue: 399 millions d'euros
  • Revenue growth: 3,9 %

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours